Skip to main content
Erschienen in: Supportive Care in Cancer 5/2011

01.05.2011 | Short Communication

Development and pilot testing of a communication aid to assist clinicians to communicate with women diagnosed with ductal carcinoma in situ (DCIS)

verfasst von: Simone E. De Morgan, Phyllis N. Butow, Elizabeth A. Lobb, Melanie A. Price, Caroline Nehill

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The literature highlights the confusion amongst women diagnosed with ductal carcinoma in situ (DCIS) about aspects of their disease and treatment and the wide variation in how doctors communicate about DCIS. The DCIS communication aid (CA) was developed to assist clinicians to communicate with women diagnosed with DCIS and to improve women's understanding about their disease, prognosis and treatment options. This study aimed to assess patient and clinician perceptions of the CA.

Methods

The CA included information and diagrams about key aspects of the diagnosis, prognosis, treatment and support. It was designed to be used in clinical consultations and taken home after the consultation. Australian women with DCIS (n=18) participated in structured interviews and clinicians (n=7), including surgeons and radiation oncologists, completed surveys to assess their perceptions of the CA. Main outcome measures included satisfaction with the content, design and diagrams in the CA, and perceptions of the benefits of the CA and its impact on doctor–patient communication.

Results

All clinicians and women with DCIS reported that the CA would assist communication and help women understand their diagnosis.

Conclusions

This is the first intervention designed to decrease the confusion amongst women with DCIS and improve doctor–patient communication in this area. This study highlights that interventions such as the DCIS communication aid may be a valuable resource for clinicians and women with DCIS. This study also highlights key communication challenges relating to DCIS.
Literatur
1.
Zurück zum Zitat Arpino G, Laucirica R, Elledge R (2005) Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 143:446–457PubMed Arpino G, Laucirica R, Elledge R (2005) Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 143:446–457PubMed
2.
Zurück zum Zitat Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97:135–144PubMedCrossRef Erbas B, Provenzano E, Armes J, Gertig D (2006) The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 97:135–144PubMedCrossRef
3.
Zurück zum Zitat Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96:906–920PubMedCrossRef Leonard GD, Swain SM (2004) Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 96:906–920PubMedCrossRef
4.
Zurück zum Zitat De Morgan S, Redman S, White KJ, Cakir B, Boyages J (2002) "Well, have I got cancer or haven't I?" The psycho-social issues for women diagnosed with ductal carcinoma in situ. Health Expect 5:310–318PubMedCrossRef De Morgan S, Redman S, White KJ, Cakir B, Boyages J (2002) "Well, have I got cancer or haven't I?" The psycho-social issues for women diagnosed with ductal carcinoma in situ. Health Expect 5:310–318PubMedCrossRef
5.
Zurück zum Zitat Welch HG, Woloshin S, Schwartz (2008) The sea of uncertainty surrounding ductal carcinoma in situ- the price of screening mammography. J Natl Cancer Inst 100:228–229PubMedCrossRef Welch HG, Woloshin S, Schwartz (2008) The sea of uncertainty surrounding ductal carcinoma in situ- the price of screening mammography. J Natl Cancer Inst 100:228–229PubMedCrossRef
6.
Zurück zum Zitat Virnig BA, Tuttle TM, Shamliyan, Kane RL (2010) Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and options. J Natl Cancer Inst 102:170–178PubMedCrossRef Virnig BA, Tuttle TM, Shamliyan, Kane RL (2010) Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and options. J Natl Cancer Inst 102:170–178PubMedCrossRef
7.
Zurück zum Zitat Bijker N, Meihnen P, Johannes LP, Peterse JB, Van Hoorebeeck IV, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387PubMedCrossRef Bijker N, Meihnen P, Johannes LP, Peterse JB, Van Hoorebeeck IV, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381–3387PubMedCrossRef
8.
Zurück zum Zitat Tang P, Hajdu SI, Lyman GH (2007) Ductal carcinoma in situ: a review of recent advances. Obstet Gynecol 19:63–67 Tang P, Hajdu SI, Lyman GH (2007) Ductal carcinoma in situ: a review of recent advances. Obstet Gynecol 19:63–67
9.
Zurück zum Zitat Silverstein MJ (2003) The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186:337–343PubMedCrossRef Silverstein MJ (2003) The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 186:337–343PubMedCrossRef
10.
Zurück zum Zitat De Morgan S, Redman S, D’Este C, Rogers K (2010) Knowledge, satisfaction with information, decisional conflict and psychological morbidity amongst women diagnosed with ductal carcinoma in situ (DCIS). Patient Educ Couns doi:10.1016/j.pec.2010.07.002 De Morgan S, Redman S, D’Este C, Rogers K (2010) Knowledge, satisfaction with information, decisional conflict and psychological morbidity amongst women diagnosed with ductal carcinoma in situ (DCIS). Patient Educ Couns doi:10.​1016/​j.​pec.​2010.​07.​002
11.
Zurück zum Zitat Kennedy F, Harcourt D, Rumsey N (2008) The challenge of being diagnosed and treated for ductal carcinoma in situ (DCIS). Eur J Oncol Nurs 12:103–111PubMedCrossRef Kennedy F, Harcourt D, Rumsey N (2008) The challenge of being diagnosed and treated for ductal carcinoma in situ (DCIS). Eur J Oncol Nurs 12:103–111PubMedCrossRef
12.
Zurück zum Zitat Patridge A, Adloff K, Blood E, Dees C, Kaelin C, Golshan M, Ligibel J, De Moor JS, Weeks J, Winer E (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100:243–251CrossRef Patridge A, Adloff K, Blood E, Dees C, Kaelin C, Golshan M, Ligibel J, De Moor JS, Weeks J, Winer E (2008) Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study. J Natl Cancer Inst 100:243–251CrossRef
13.
Zurück zum Zitat van Gestel YRBM, Voogd AC, Vingerhoets AJJM, Mols F, Nieuwenhuijzen GAP, van Driel OJ, van Berlo CLH, van de Poll-Franse LV (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 47:549–556 van Gestel YRBM, Voogd AC, Vingerhoets AJJM, Mols F, Nieuwenhuijzen GAP, van Driel OJ, van Berlo CLH, van de Poll-Franse LV (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 47:549–556
14.
Zurück zum Zitat Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol J-P, Paszat L et al (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77:285–293PubMedCrossRef Rakovitch E, Franssen E, Kim J, Ackerman I, Pignol J-P, Paszat L et al (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77:285–293PubMedCrossRef
15.
Zurück zum Zitat Whelan T, Levine M, Willan A, Gafni A, Sanders K, Mirsky D, Chambers S, O’Brien M, Reid S, Dubois S (2004) Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery. JAMA 292:435–441PubMedCrossRef Whelan T, Levine M, Willan A, Gafni A, Sanders K, Mirsky D, Chambers S, O’Brien M, Reid S, Dubois S (2004) Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery. JAMA 292:435–441PubMedCrossRef
16.
Zurück zum Zitat Silvia KA, Sepucha KR (2006) Decision aids in routine practice: lessons from the breast cancer initiative. Health Expect 9:225–264CrossRef Silvia KA, Sepucha KR (2006) Decision aids in routine practice: lessons from the breast cancer initiative. Health Expect 9:225–264CrossRef
17.
Zurück zum Zitat Lobb EA, Butow PH, Moore A, Barratt A, Tucker K, Gaff C, Kirk J, Dudding T, Butt D (2006) Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: A pilot study. J Genet Couns 15:393–405PubMedCrossRef Lobb EA, Butow PH, Moore A, Barratt A, Tucker K, Gaff C, Kirk J, Dudding T, Butt D (2006) Development of a communication aid to facilitate risk communication in consultations with unaffected women from high risk breast cancer families: A pilot study. J Genet Couns 15:393–405PubMedCrossRef
18.
Zurück zum Zitat Fleisher L, Buzaglo J, Collins M, Millard J, Miller SM, Egleston BL, Solarino N, Trinastic J, Cegala DJ, Benson AB, Schulman KA, Weinfurt KP, Sulmasy D, Diefenbach MA, Meropol NJ (2008) Using health communication best practices to develop a web-based provider–patient communication aid: The CONNECTTM study. Patient Educ Counsel 71:378–387CrossRef Fleisher L, Buzaglo J, Collins M, Millard J, Miller SM, Egleston BL, Solarino N, Trinastic J, Cegala DJ, Benson AB, Schulman KA, Weinfurt KP, Sulmasy D, Diefenbach MA, Meropol NJ (2008) Using health communication best practices to develop a web-based provider–patient communication aid: The CONNECTTM study. Patient Educ Counsel 71:378–387CrossRef
19.
Zurück zum Zitat O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, EntwistleVA, Fiset V, Holmes-Rovner M, Khangura S, Llewellyn-Thomas H, Rovner D (2009) Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD001431. doi:10.1002/14651858.CD001431.pub2 O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, EntwistleVA, Fiset V, Holmes-Rovner M, Khangura S, Llewellyn-Thomas H, Rovner D (2009) Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD001431. doi:10.​1002/​14651858.​CD001431.​pub2
20.
Zurück zum Zitat O’Connor AM, Fiset V, DeGrasse C, Graham ID, Evans W, Stacey D, Laupacis A, Tugwell P (1999) Decision aids for patients considering options affecting cancer outcomes: evidence or efficacy and policy implications. J Natl Cancer Inst Monogr 25:67–80PubMed O’Connor AM, Fiset V, DeGrasse C, Graham ID, Evans W, Stacey D, Laupacis A, Tugwell P (1999) Decision aids for patients considering options affecting cancer outcomes: evidence or efficacy and policy implications. J Natl Cancer Inst Monogr 25:67–80PubMed
21.
Zurück zum Zitat O’Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E, Hollingworth G, McPherson R, Bunn H, Graham I, Drake E (1998) A decision aid for women considering hormone therapy after menopause: Decision support framework and evaluation. Patient Educ Counsel 33:267–279CrossRef O’Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E, Hollingworth G, McPherson R, Bunn H, Graham I, Drake E (1998) A decision aid for women considering hormone therapy after menopause: Decision support framework and evaluation. Patient Educ Counsel 33:267–279CrossRef
22.
Zurück zum Zitat Juraskova I, Butow P, Lopez A, Seccombe M, Coates A, Boyle F, McCarthy N, Reaby L, Forbes JF (2008) Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS). Health Expect 11:252–262PubMedCrossRef Juraskova I, Butow P, Lopez A, Seccombe M, Coates A, Boyle F, McCarthy N, Reaby L, Forbes JF (2008) Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS). Health Expect 11:252–262PubMedCrossRef
23.
Zurück zum Zitat Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C et al (1995) Effects of individualized breast cancer risk counseling: A randomized trail. J Natl Cancer Inst 87:286–301PubMedCrossRef Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C et al (1995) Effects of individualized breast cancer risk counseling: A randomized trail. J Natl Cancer Inst 87:286–301PubMedCrossRef
24.
Zurück zum Zitat Lipkus IM, Hollands JG (1999) The visual communication of risk. J Natl Cancer Inst Monogr 25:149–163PubMed Lipkus IM, Hollands JG (1999) The visual communication of risk. J Natl Cancer Inst Monogr 25:149–163PubMed
25.
Zurück zum Zitat Patton MQ (2001) Qualitative research and evaluation methods, 2nd edn. Sage Publications, Thousand Oaks Patton MQ (2001) Qualitative research and evaluation methods, 2nd edn. Sage Publications, Thousand Oaks
Metadaten
Titel
Development and pilot testing of a communication aid to assist clinicians to communicate with women diagnosed with ductal carcinoma in situ (DCIS)
verfasst von
Simone E. De Morgan
Phyllis N. Butow
Elizabeth A. Lobb
Melanie A. Price
Caroline Nehill
Publikationsdatum
01.05.2011
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-1040-5

Weitere Artikel der Ausgabe 5/2011

Supportive Care in Cancer 5/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.